Home / Treatments / Radiation Oncology
Radiation Oncology denials: what the review data shows
Independent reviewers have decided 150 published cases where an insurer denied Radiation Oncology — and they overturned the insurer 38.7% of the time. A denial for Radiation Oncology is a starting position, not a final answer.
Published decisions
150
2001–2026
Overturned
38.7%
58 denials reversed
Conditions behind radiation oncology denials
What insurers denied — and how those fights ended.
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 99 | 48.5% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 50 | 18% |
Typical time to a decision
7 days
Most land between 6 and 10 days
Handled as urgent
77.3%
Expedited when a delay would cause harm
Recent direction
Rising
34.9% → 44.8% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Physician 1: The patient is a 64-year-old male who was diagnosed with a well-differentiated adenocarcinoma of the pancreas on 7/22/04. The mass was in the head of the pancreas measuring 2.5cm in diameter and had encased the superior mesenteric artery. Following evaluations, the patient was given chemotherapy followed by conventional radiology as a step towards a definitive surgery. Since November 2004, the patient has been evaluated by various cancer centers and has been found to have a surgically unresectable tumor. It has been recommended the patient undergo intensity-modulated radiation therapy (IMRT) as a step towards a definitive approach. The Health Plan has denied authorization and coverage for IMRT on the basis it is considered experimental. It is well known and accepted that cancer of the pancreas carries a reputation of poor prognosis.
Physician 1: The patient is a 61-year-old male diagnosed with a low-grade adenocarcinoma of the prostate in July 1998. At that time, he elected to undergo watchful waiting. More recently, his PSA rose to 7.4 in June 2005. Repeat biopsy revealed a Gleason score of 3+2=5/10, three of eleven core biopsies were positive. Physical examination was consistent with a clinical stage T2a. According to the radiation oncologist consult note, options regarding definitive treatment were discussed and the patient “appears to favor treatment with prostate brachytherapy.” The records are unclear as to why the patient did not undergo a brachytherapy implant, but rather, received IMRT fractionated radiotherapy to the prostate. He was treated with the IMRT technique to the prostate with 6 MV photons, utilizing IGRT techniques to deliver a tumor dose of 7560 cGy.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Physician 1The patient is a 51-year-old woman who was diagnosed with left breast cancer in December 2003. At that time she was found to have a 1.3cm invasive ductal carcinoma with two positive nodes, one of which apparently was palpable to the surgeon. She has been treated with adjuvant chemotherapy including Adriamycin, Cytoxan, and Taxotere. Since her surgery was a segmental mastectomy, she now requires radiation therapy to the breast.The patient has been seen by radiation therapy who discussed the technique of whole breast radiation, including possible toxicities. It has been proposed the patient receive radiation only to the area of the tumor, using intensity-modulated radiation therapy (IMRT).It is standard and advisable for women who undergo less than a mastectomy to undergo radiation therapy to the breast.
Physician 1: The patient is a 64-year-old female diagnosed with breast cancer that underwent lumpectomy and lymph node sampling in February 2006. She was staged at T1b No Mo with 9mm infiltrating ductal carcinoma, SBR 6/9. The patient was also treated with Accelerated Partial Breast Irradiation (APBI) between February 2006 and March 2006 for a total of eight sessions of 4.3 Gy per session for which she is now seeking reimbursement. The Health Plan denied her request citing the investigational nature of the therapy.The American Brachytherapy Society (ABS) and the American College of Breast Surgeons (ACBS) have suggested that partial breast irradiation is an accepted technique for early breast cancer with negative nodes. Although a non-randomized study indicates APBI may be as effective as whole breast irradiation, additional research is still on-going.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
How to use this in your appeal
These are outcomes from California’s external review program — an independent physician panel that binds the insurer. Every state has an equivalent process, and internal appeals succeed even more often. Cite the outcome record for Radiation Oncologywhen you appeal: reviewers routinely find that denials like yours didn’t hold up.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.